OA10510A - Process and crystal forms of 2-methyl-thieno-benzodiazepine - Google Patents

Process and crystal forms of 2-methyl-thieno-benzodiazepine Download PDF

Info

Publication number
OA10510A
OA10510A OA70082A OA70082A OA10510A OA 10510 A OA10510 A OA 10510A OA 70082 A OA70082 A OA 70082A OA 70082 A OA70082 A OA 70082A OA 10510 A OA10510 A OA 10510A
Authority
OA
OAPI
Prior art keywords
olanzapine
methyl
polymorph
lessthan
disorder
Prior art date
Application number
OA70082A
Other languages
English (en)
Inventor
Charles A Bunnell
Barry A Hendriksen
Samuel D Larsen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of OA10510A publication Critical patent/OA10510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
OA70082A 1995-03-24 1997-09-24 Process and crystal forms of 2-methyl-thieno-benzodiazepine OA10510A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
OA10510A true OA10510A (en) 2002-04-24

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70082A OA10510A (en) 1995-03-24 1997-09-24 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Country Status (49)

Country Link
US (1) US5736541A (fr)
EP (3) EP1445259B1 (fr)
JP (1) JPH11502535A (fr)
KR (1) KR100399688B1 (fr)
CN (1) CN1065536C (fr)
AP (1) AP828A (fr)
AR (2) AR010448A1 (fr)
AT (4) ATE251627T1 (fr)
AU (1) AU706471B2 (fr)
BG (1) BG62619B1 (fr)
BR (1) BR9607790A (fr)
CA (1) CA2214005C (fr)
CH (1) CH690579A5 (fr)
CO (1) CO4650278A1 (fr)
CZ (1) CZ292688B6 (fr)
DE (4) DE69636313T2 (fr)
DK (4) DK0733635T3 (fr)
EA (1) EA000149B1 (fr)
EE (1) EE03489B1 (fr)
EG (1) EG23659A (fr)
ES (3) ES2266719T3 (fr)
FI (1) FI973750A (fr)
GB (1) GB2313835B (fr)
HK (1) HK1013988A1 (fr)
HU (1) HU224989B1 (fr)
IL (1) IL117610A (fr)
IS (1) IS1896B (fr)
LT (1) LT4349B (fr)
LU (1) LU90096B1 (fr)
LV (1) LV12018B (fr)
MY (1) MY114701A (fr)
NO (1) NO314663B1 (fr)
NZ (1) NZ306110A (fr)
OA (1) OA10510A (fr)
PA (1) PA8353701A1 (fr)
PE (1) PE44897A1 (fr)
PL (1) PL183723B1 (fr)
PT (3) PT1095941E (fr)
RO (1) RO118872B1 (fr)
SE (1) SE9703205D0 (fr)
SI (4) SI9620040B (fr)
SK (1) SK284143B6 (fr)
SV (1) SV1996000031A (fr)
TR (1) TR199701017T1 (fr)
TW (2) TW442488B (fr)
UA (1) UA44765C2 (fr)
WO (1) WO1996030375A1 (fr)
YU (1) YU49478B (fr)
ZA (2) ZA962344B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EP0852496A4 (fr) * 1995-09-29 1998-11-11 Lilly Co Eli Methode de traitement d'un tic chronique
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
NZ332037A (en) * 1996-03-25 2001-01-26 Lilly Co Eli Olanzapine for treating migraine pain
WO1997035585A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Methode d'anesthesie
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
WO1997035583A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Procede de traitement de la douleur
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
WO1998046596A1 (fr) * 1997-04-15 1998-10-22 Eli Lilly And Company Methode destinee a produire des effets neuro-protecteurs
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CA2344873A1 (fr) * 1998-09-30 2000-04-06 Eli Lilly And Company Formulation de 2-methyl-thieno-benzodiazepine
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
PT1246827E (pt) * 1999-12-28 2005-08-31 Cipla Ltd Novas formas polimerficas da olanzapina
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2002018390A1 (fr) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Procede de preparation d'hydrates d'olanzapine et de conversion de ceux-ci en formes cristallines d'olanzapine
WO2002019998A2 (fr) * 2000-09-08 2002-03-14 Eli Lilly And Company Traitement des prises de poids associees a l'utilisation d'antipsychotiques atypiques
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004089313A2 (fr) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Nouvelles formes de l'olanzapine et methodes de traitement associees
EP2266590A3 (fr) 2002-02-22 2011-04-20 Shire LLC Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) * 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (fr) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Nouvelles formes cristallines d'olanzapine, procedes pour les preparer et procede pour preparer des formes cristallines d'olanzapine connues
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
WO2004108700A1 (fr) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Procedes de preparation de formes polymorphiques de la desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (fr) * 2003-11-18 2005-06-02 3M Innovative Properties Company Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine
DE602004014264D1 (de) * 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
EP1709053B1 (fr) 2004-01-27 2011-04-06 Synthon B.V. Sels stables d'olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EP2623095A1 (fr) * 2004-11-16 2013-08-07 Elan Pharma International Limited Formulations injectables de nanoparticules d'olanzapine
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2006102176A2 (fr) * 2005-03-21 2006-09-28 Dr. Reddy's Laboratories Ltd. Procede de preparation d'une forme cristalline i d'olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (fr) * 2005-08-17 2007-02-22 Synthon B.V. Procede de fabrication d’olanzapine de forme i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (fr) * 2006-05-18 2007-11-29 Synthon B.V. Composition pharmaceutique d'olanzapine
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (fr) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Nouvelles methodes de synthese de la forme-i de l'olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
FI3446565T3 (fi) 2010-08-23 2024-01-30 Alkermes Pharma Ireland Ltd Menetelmiä antipsykoottisten lääkkeiden aiheuttaman painonnousun hoitamiseksi
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (fr) 2011-05-04 2012-11-15 Zentiva K.S. Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
AU2013305884B2 (en) 2012-08-21 2017-10-05 Saladax Biomedical Inc. Antibodies to risperidone haptens and use thereof
CN104755093B (zh) * 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (fr) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, ses compositions et méthodes d'utilisation associées

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (fr) 1977-07-20 1981-03-10 George K. E. Gregory Emballages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
DE69329887T2 (de) * 1992-05-29 2001-05-23 Lilly Co Eli Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
KR19980703188A (ko) 1998-10-15
LV12018A (lv) 1998-04-20
LU90096B1 (fr) 1997-07-22
DK0733635T3 (da) 2001-10-08
SK121897A3 (en) 1998-03-04
CO4650278A1 (es) 1998-09-03
DK1445259T3 (da) 2006-10-16
DK1095941T3 (da) 2004-02-16
GB2313835B (en) 1998-09-16
SI9620040B (sl) 2002-02-28
DE19681286T1 (de) 1998-04-02
NO974365D0 (no) 1997-09-22
WO1996030375A1 (fr) 1996-10-03
IL117610A (en) 2001-08-26
GB2313835A (en) 1997-12-10
MX9707183A (es) 1997-11-29
PL322501A1 (en) 1998-02-02
UA44765C2 (uk) 2002-03-15
PE44897A1 (es) 1997-10-22
TW442488B (en) 2001-06-23
BR9607790A (pt) 1998-07-07
DE69630324D1 (de) 2003-11-13
CA2214005C (fr) 2001-07-03
YU17796A (sh) 1999-03-04
CA2214005A1 (fr) 1996-10-03
CH690579A5 (de) 2000-10-31
SI9620040A (sl) 1998-06-30
EE03489B1 (et) 2001-08-15
ATE331719T1 (de) 2006-07-15
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
AP828A (en) 2000-04-28
MY114701A (en) 2002-12-31
SE9703205L (sv) 1997-09-05
NO314663B1 (no) 2003-04-28
ES2266719T3 (es) 2007-03-01
ZA962344B (en) 1997-09-22
HK1013988A1 (en) 1999-09-17
EP1095941A1 (fr) 2001-05-02
SV1996000031A (es) 1998-03-27
LT97148A (en) 1998-01-26
SI0733635T1 (en) 2002-06-30
SE9703205D0 (sv) 1997-09-05
ATA902196A (de) 2000-01-15
IS1896B (is) 2003-10-20
DE69636313T2 (de) 2007-05-31
CN1065536C (zh) 2001-05-09
ES2208220T3 (es) 2004-06-16
US5736541A (en) 1998-04-07
CN1179160A (zh) 1998-04-15
EA000149B1 (ru) 1998-10-29
NO974365L (no) 1997-09-22
SI1095941T1 (en) 2003-12-31
TW513432B (en) 2002-12-11
FI973750A0 (fi) 1997-09-22
ZA962342B (en) 1997-09-22
ATE204280T1 (de) 2001-09-15
PL183723B1 (pl) 2002-07-31
PT733635E (pt) 2001-12-28
RO118872B1 (ro) 2003-12-30
BG101900A (en) 1999-03-31
LT4349B (lt) 1998-05-25
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
DE69614426D1 (de) 2001-09-20
DE69636313D1 (de) 2006-08-10
EP0733635A1 (fr) 1996-09-25
CZ300097A3 (en) 1997-12-17
SK284143B6 (sk) 2004-10-05
AT406771B (de) 2000-08-25
EP0733635B1 (fr) 2001-08-16
AR002719A1 (es) 1998-04-29
IS4564A (is) 1997-09-22
AU706471B2 (en) 1999-06-17
BG62619B1 (bg) 2000-03-31
HUP9802824A3 (en) 2000-01-28
JPH11502535A (ja) 1999-03-02
PT1095941E (pt) 2004-02-27
LV12018B (en) 1998-09-20
EP1445259B1 (fr) 2006-06-28
ES2159346T3 (es) 2001-10-01
NZ306110A (en) 1998-09-24
FI973750A (fi) 1997-09-22
ATE251627T1 (de) 2003-10-15
DK108997A (da) 1997-11-12
EP1095941B1 (fr) 2003-10-08
EE9700232A (et) 1998-04-15
DE69614426T2 (de) 2002-05-23
YU49478B (sh) 2006-05-25
SI1445259T1 (sl) 2006-10-31
EA199700262A1 (ru) 1998-02-26
HU224989B1 (en) 2006-05-29
KR100399688B1 (ko) 2004-02-18
EP1445259A1 (fr) 2004-08-11
TR199701017T1 (xx) 1998-01-21
HUP9802824A2 (hu) 1999-06-28
EG23659A (en) 2007-03-26
IL117610A0 (en) 1996-07-23
DE69630324T2 (de) 2004-07-29
AU5427996A (en) 1996-10-16
CZ292688B6 (cs) 2003-11-12
GB9719819D0 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
OA10510A (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine
AU720366B2 (en) Olanzapine dihydrate D
US5703232A (en) Process and solvate of 2-methyl-thieno-benzodiazepine
AU719441B2 (en) Intermediates and process for preparing olanzapine
HUT77907A (hu) 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
MXPA98007430A (en) Medications for the treatment of the car